CJC-1295 DAC vs no-DAC

A missing attachment changes the compound. A nearly identical name makes that easy to overlook.

The shared peptide sequence

Both names lead back to a modified GHRH fragment. The peptide has 29 amino acids, with substitutions at positions 2, 8, 15 and 27. These changes help it resist breakdown. The early chemistry paper describes the long-acting albumin-conjugating design; the Modified GRF (1-29) reference describes the short-acting form.

I initially treated “no-DAC” as a minor qualifier. The chemistry makes that casual reading untenable. Removing the albumin-binding part takes away the feature responsible for the striking multi-day human pharmacokinetics.

The DAC attachment

DAC stands for Drug Affinity Complex. In CJC-1295 it supplies a chemical handle that forms a covalent bond with albumin—a firm chemical attachment to a circulating blood protein. The rat and laboratory work examined this conjugation and the resulting prolonged exposure.

The human study then estimated a 5.8-8.1-day half-life for CJC-1295 DAC. That figure has a specific chemical identity attached to it. I regard the attachment as the main event in this design, rather than an optional extra to a familiar name.

A small rose thread chain stitched onto a much larger folded paper form — A constructed paper-and-thread illustration of attachment to a larger carrier; it does not reproduce molecular geometry.

Modified GRF 1-29 without DAC

The no-DAC form retains the stabilising substitutions and lacks the albumin-binding moiety. The reference description distinguishes it from the long-acting CJC-1295 DAC compound. Its action is short, in the minutes-to-hours range, and matching published human pharmacokinetic evidence is lacking.

The important asymmetry is in the evidence as well as the chemistry. The long-acting form has the published healthy-volunteer timing results. The short-acting form cannot acquire those results simply because both names include CJC-1295.

Which form did the human papers test?

The Teichman hormone and half-life study and the Ionescu/Frohman pulsatility study concern the long-acting compound. Their findings describe days of altered hormone levels after the DAC form was given.

My rule for this particular dispute is uncompromising: the chemical identity has to survive the retelling. A summary that changes the form has changed the question. The research record places the experiments in sequence; the study-amount page keeps the populations and units beside the amounts.

Duration and safety

Albumin attachment prolongs exposure. The safety questions include fluid retention, insulin sensitivity, immune reactions and sustained IGF-1 elevation, discussed in the FDA advisory materials and the review of GHRH analogs.

Neither form has an approved human indication. The comparison here establishes why their timing differs; a comparative long-term safety verdict would need clinical evidence that the current record does not supply. The effects page separates reported symptoms from those wider biological concerns.